tiprankstipranks

Ideaya trial design consisent with guidance, says Oppenheimer

Oppenheimer reiterates an Outperform rating on Ideaya Biosciences (IDYA) with a $40 price target after the company announced that it met with the FDA to finalize the design of darovasertib’s Phase 3 trial in the neoadjuvant setting. The FDA ratified Ideaya’s proposed endpoints for the trial, the analyst tells investors in a research note. The firm says the use of “no detriment” event-free-survival as a secondary “strikes a happy medium.” It views the trial design as consistent with Ideaya’s previous guidance.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue